AstraZeneca

Headlines · 5

1. 2d
   AstraZeneca CFO says AI is used across nearly all company work

   AstraZeneca CFO Aradhana Sarin said the drug company uses AI in almost every aspect of its work. Bloomberg Technology’s interview also covered earnings, the drug pipeline, dealmaking and a restructuring plan, but provided no details about specific AI systems or measured outcomes.

   Bloomberg Technology · 🔥 3
2. 2d
   PerturbMind AI launches AlphaCell 1.0 Pro for omics drug discovery

   PerturbMind AI has emerged from stealth, announced angel and angel+ financing totaling tens of millions of yuan, and launched the PerturbSeek digital-life world-model ecosystem. The company released AlphaCell 1.0 Pro, a geometric world model for virtual-cell state and perturbation-trajectory inference. The standard version has 1 billion parameters, with configurable versions ranging from 300 million to 50 billion parameters. PerturbMind AI says the model can support disease-mechanism analysis, target discovery and drug-response modeling. The reports state that its ability to understand complex biological systems still requires continued experimental validation and testing in actual drug-development projects.

   MIT科技评论中文 · 🔥 3
3. Oct 23
   Pathos AI Raises $237M Series E at $3B Valuation

   Pathos AI announced a $237 million Series E financing at a $3 billion post-money valuation, led by Bristol Myers Squibb with participation from several unnamed returning backers. The company develops cancer drugs with its agentic AI platform, Foundry, which it says can access about 200 petabytes of oncology data. Pathos also announced agreements with Bristol Myers Squibb and Tempus AI involving Foundry access and de-identified data on Alzheimer's disease and other neurological conditions. The supplied reports do not independently validate the platform's performance claims or provide independent clinical-outcome data for Foundry-assisted development.

   SiliconANGLE AI · 🔥 0
4. Oct 20
   AstraZeneca and Oracle sign non-binding AI deal to find clinical trial patients

   AstraZeneca and Oracle announced a non-binding term sheet to explore using AI and real-world health data to identify patients eligible for clinical trials, speed up medical evidence generation and feed findings into routine care. AstraZeneca contributes drug-science, trial and regulatory expertise, while Oracle's health unit brings cloud infrastructure, AI tools and hospital patient data with names removed; AstraZeneca said it will not see patient identities and that each project proceeds only after legal, privacy and ethics checks. The first programme will run in Abu Dhabi with UAE healthcare company M42, targeting people with uncontrolled high blood pressure, with later projects planned in the US, the Middle East and Europe across oncology, cardiovascular, renal and metabolic, respiratory and immunology, and rare diseases. Neither company disclosed financial terms.

   36氪快讯 · 🔥 0
5. Oct 13
   AI drug discovery hits a wet-lab data bottleneck after its sprint

   A Shenlan Guan article republished by Huxiu AI argues that AI is already embedded in pharma R&D workflows — literature review, molecule generation and trial-progress dashboards — but faster work does not mean higher success rates, since public biomedical data is downloadable by anyone and forms no moat. The piece says leading players are therefore moving into wet labs and running design–build–test–learn loops to accumulate proprietary data, citing Eli Lilly's Lilly TuneLab signing GenScript, Twist Bioscience and Ginkgo Bioworks on September 16 to supply wet-lab data, and a reported Anthropic biology wet lab in the San Francisco Bay Area. It concludes AI remains an assistant that proposes hypotheses rather than a decision system, and that wet-lab throughput and biological timelines cap proprietary data at linear growth, forcing AI pharma to slow down.

   虎嗅 AI · 🔥 0

Experience and discussion from the community

Share my AstraZeneca experienceAsk about AstraZeneca